- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Changes to MEOS and Barriers to Entry
As terms for Monthly Enhanced Oncology Services (MEOS) payments are set to change under the EOM, panelists worry that the barriers to entry to value-based care will be too high for practices that did not participate in the OCM.
EP: 1.No Successor to OCM Would Disappoint
EP: 2.CMMI Open to Feedback, but EOM Out of the Blue
EP: 3.Some Practices That Did Not Do OCM Are Applying
EP: 4.Seven Tumor Types: Pros and Cons
EP: 5.A Model That Is Built to “Win”
EP: 6.Addressing Health Equity and Social Needs
EP: 7.Is Five Years Long Enough?
EP: 8.Changes to MEOS and Barriers to Entry
EP: 9.Small Practices and Dual Risk: Considerations and Approaches
EP: 10.Does Pooling Make Sense?
EP: 11.What Would You Change About the EOM?
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, takes the discussion where everyone wants it to go: MEOS payments. What will lower payments—from $160 per patient per month to $70 for most patients, and $100 for those dually eligible for Medicare and Medicaid, mean for practices? Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, highlights the lack of a copayment for patients as a plus of the EOM, and says it’s good there is extra revenue tied to caring for the Medicaid population. But Divers and Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, both express concern about the barrier to entry issue for practices that most need to try value-based care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, says that CMMI would benefit from broader thinking about rewarding practices for attending to the global cost of care. Divers also notes the effect that inflation has had on practices, as the cost of supplies has increased.
For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal
July 15th 2025CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
Read More
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Read More
